Table 2. Cross-Sectional Utilization of Weight Management Treatments Among Patients With Obesity in 2017 and 2019a.
| Weight management treatment | Patients, % (95% CI) | Difference, AME (95% CI)b (n = 37 245c) | |
|---|---|---|---|
| 2017 (n = 30 742) | 2019 (n = 17 796) | ||
| Nutrition services | 2.8 (2.6 to 3.0) | 3.2 (3.0 to 3.5) | 0.4 (0.1 to 0.7) |
| Low-calorie meal replacement | 0.6 (0.5 to 0.6) | 0.5 (0.4 to 0.7) | −0.0 (−0.2 to 0.1) |
| Weight-management medications | 2.1 (1.9 to 2.2) | 3.4 (3.1 to 3.6) | 1.3 (0.1 to 1.6) |
| GLP1RAd | 2.4 (2.3 to 2.6) | 4.2 (3.9 to 4.5) | 1.7 (1.4 to 2.1) |
| Patients without prior bariatric surgery, No. | 30 694 | 17 721 | 37 1792 |
| Bariatric surgery | 0.1 (0.1 to 0.2) | 0.3 (0.2 to 0.4) | 0.2 (0.1 to 0.2) |
| Any weight management treatmente | 5.3 (5.1 to 5.6) | 7.1 (6.7 to 7.4) | 1.7 (1.3 to 2.2) |
Abbreviations: AME, Average Marginal Effect; GLP1RA, glucagon-like peptide-1 receptor agonists.
a
Utilization is estimated during the year following a patient’s first weight measurement in each year for patients with a full year of follow-up. We exclude patients with prior bariatric surgery when estimating bariatric surgery utilization.
b
Differences are average marginal effect estimates for year from an unadjusted logistic regression model fit using generalized estimating equations clustered on patient.
c
Number of unique patients.
d
During the study timeframe, GLP1RA were not approved for weight-loss, but are included here separately given their effectiveness for weight-loss.
e
Does not include GLP1RA.